RLAY
Relay Therapeutics Inc

1,114
Mkt Cap
$1.1B
Volume
2.14M
52W High
$7.64
52W Low
$1.78
PE Ratio
-3.62
RLAY Fundamentals
Price
$6.38
Prev Close
$6.34
Open
$6.54
50D MA
$5.93
Beta
1.80
Avg. Volume
1.88M
EPS (Annual)
-$2.36
P/B
1.80
Rev/Employee
$38,341.00
Loading...
Loading...
News
all
press releases
Persistent Asset Partners Ltd Decreases Stock Position in Relay Therapeutics, Inc. $RLAY
Persistent Asset Partners Ltd trimmed its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 89.8% during the second quarter, according to the company in its most recent filing with...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Relay Therapeutics, Inc. $RLAY Holdings Increased by Savant Capital LLC
Savant Capital LLC lifted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 113.7% in the second quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·3d ago
News Placeholder
Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.1% - Still a Buy?
Relay Therapeutics (NASDAQ:RLAY) Trading 6.1% Higher - Here's What Happened...
MarketBeat·6d ago
News Placeholder
Research Analysts Set Expectations for RLAY FY2025 Earnings
Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings estimates for shares of Relay Therapeutics in a report issued on Monday...
MarketBeat·7d ago
News Placeholder
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Zacks·9d ago
News Placeholder
IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars
Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.
Zacks·9d ago
News Placeholder
Relay Therapeutics (NASDAQ:RLAY) Issues Quarterly Earnings Results
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, missing the consensus...
MarketBeat·12d ago
News Placeholder
Relay Therapeutics (NASDAQ:RLAY) Price Target Raised to $6.00 at Wells Fargo & Company
Wells Fargo & Company increased their price target on shares of Relay Therapeutics from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat...
MarketBeat·14d ago
News Placeholder
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·21d ago

Latest RLAY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.